To stop or not to stop an asthma biologic, that is the question-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

To stop or not to stop an asthma biologic, that is the question

Published:2024-09 Issue:3 Volume:133 Page:236-237
ISSN:1081-1206
Container-title:Annals of Allergy, Asthma & Immunology
language:en
Short-container-title:Annals of Allergy, Asthma & Immunology

Author:

Philipenko Brianne S.,Davis Beth,Cockcroft Donald W.^ORCID

Publisher

Elsevier BV

Reference10 articles.

1. Biomarkers and clinical outcomes after tezepelumab cessation: extended follow-up from the 2-year DESTINATION study;Brightling;Ann Allergy Asthma Immunol,2024

2. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study;Menzies-Gow;Lancet Respir Med,2023

3. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study);Moore;Eur Respir J,2022

4. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy;Ledford;J Allergy Clin Immunol,2017

5. Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis;Cavalli;Expert Rev Clin Immunol,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP